impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

Leptin and adiponectin as predictors of disease activity in rheumatoid arthritis

1, 2, 3, 4, 5, 6, 7

 

  1. Hospital General de Cuernavaca, SSM/Facultad de Farmacia, UAEM, Morelos, Cuernavaca, Mexico.
  2. Center for Population Health Research, Instituto Nacional de Salud Pública, Cuernavaca, Mexico.
  3. Facultad de Farmacia, UAEM /Facultad de Ciencias, UAEM, Morelos, Cuernavaca, Mexico.
  4. Facultad de Farmacia, UAEM /Facultad de Ciencias, UAEM, Morelos, Cuernavaca; and Depto. de Ciencias y Matemáticas, Centro Regional de Formación Docente e Investigación Educativa del Estado de Sonora, Mexico.
  5. Universidad Latinoamericana, School of Medicine, Morelos, Cuernavaca, Mexico.
  6. Universidad Latinoamericana, School of Medicine, Morelos, Cuernavaca, Mexico.
  7. Facultad de Farmacia, UAEM /Facultad de Ciencias, UAEM, Morelos, Cuernavaca, Mexico.

CER8070
2015 Vol.33, N°4
PI 0471, PF 0477
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 25936395 [PubMed]

Received: 28/10/2014
Accepted : 10/02/2015
In Press: 01/05/2015
Published: 20/07/2015

Abstract

OBJECTIVES:
To assess whether baseline levels of leptin and adiponectin predict disease activity or response to treatment in patients with RA at 6 months, 1 and 2 years of follow-up.
METHODS:
A consecutive cohort of patients, classified according to the 2010 ACR/EULAR RA criteria, was evaluated at baseline, 6 months, 1 and 2 years. All were treated with steroids and/or DMARDs. None received biologics. Blood was taken at a baseline to determine plasma anti-CCP, leptin and adiponectin. The relationship between leptin, adiponectin, DAS28 and changes in DAS28 was assessed by multivariable linear and logistic regression from baseline to follow-up.
RESULTS:
127 patients completed 6 months, 91 one year and 52 two years of follow-up. All were female, mean age 45 years (18-70), time since onset of disease 7.5 years (0-36). A U-shaped relationship between DAS28 and leptin baseline levels was seen. Adjusting for different factors, leptin levels at baseline predicted higher DAS28 at 6 months and, in patients who were not overweight or obese, predicted disease activity at 6 months, 1 and 2 years. In patients who were not overweight or obese, baseline leptin was able to predict response to treatment at 6 and 12 months.
CONCLUSIONS:
In the short term, baseline leptin levels predict disease activity in all RA patients and response to treatment in RA patients with normal weight.

Rheumatology Article